NovoCure Ltd — Director's Dealing 2020

Sep 11, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2020-09-09

Reporting Person: Shah Pritesh (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-09	Ordinary Shares	S	27621	$85.3926	Disposed	71165	Direct
2020-09-09	Ordinary Shares	S	700	$86.0736	Disposed	70465	Direct

Footnotes

F1: On September 9, 2020, pursuant to a Rule 10b5-1 adopted by Mr. Shah, Mr. Shah sold 27,621 shares in multiple trades at prices ranging from $85.00 to $85.98. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.

F2: On September 9, 2020, pursuant to a Rule 10b5-1 adopted by Mr. Shah, Mr. Shah sold 700 shares in multiple trades at prices ranging from $86.04 to $86.14. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.